Riverwater Partners, an investment management firm, published its “Micro Opportunities Strategy” investor letter for Q3 2025. A copy of the letter can be downloaded here. The strategy posted solid absolute returns in the quarter, but lagged the benchmark as it failed to keep pace with the strong rally. The strategy continues to focus on quality companies in a volatile environment. Additionally, you can check out the fund’s top five holdings to determine your best picks for 2025.
In its Q3 2025 investor letter, Riverwater Partners Micro Opportunities Strategy highlighted stocks like Delcath Systems, Inc. (NASDAQ:DCTH). Delcath Systems, Inc. (NASDAQ:DCTH) is an interventional oncology company. Delcath Systems, Inc. (NASDAQ:DCTH)’s monthly performance was 15.14% and its stock lost 16.58% in the past 52 weeks. On December 15, 2025, Delcath Systems, Inc. (NASDAQ:DCTH) stock closed at $10.08 per share, with a market capitalization of $352.961 million.
Riverwater Partners Micro Opportunities Strategy stated the following regarding Delcath Systems, Inc. (NASDAQ:DCTH) in its Q3 2025 investor letter:
“Delcath Systems, Inc. (NASDAQ:DCTH) is a commercial-stage oncology company focused on liver-targeted cancer therapies. Its proprietary Hepzato kit delivers high-dose chemotherapy directly to the liver while minimizing systemic exposure, enabling targeted treatment of metastatic cancers primarily affecting the liver. The therapy is currently approved for ocular melanoma with liver metastases, and there are ongoing trials such as CHOPIN that include first-line use and explore its potential in broader indications.
